Trial · NCT04639310
Results by group32
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 32
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change From Baseline in Monthly (28 Day) Countable Motor Seizure Frequency During the Blinded Treatment Period | XEN496 | -46.0 | Standard Deviation 23.49 | percentage change from baseline | |
| Percent Change From Baseline in Monthly (28 Day) Countable Motor Seizure Frequency During the Blinded Treatment Period | Placebo | 25.6 | Standard Deviation 46.84 | percentage change from baseline | |
| Percentage of Subjects With ≥50 Percent Reduction in Monthly (28 Day) Seizure Frequency | XEN496 | 2 | Participants | ||
| Percentage of Subjects With ≥50 Percent Reduction in Monthly (28 Day) Seizure Frequency | Placebo | 0 | Participants | ||
| Caregiver Global Impression of Change (CaGI-C) Scores for the Subject's Overall Condition and for Seizures | XEN496 | Overall Condition | 1 | Participants | |
| Caregiver Global Impression of Change (CaGI-C) Scores for the Subject's Overall Condition and for Seizures | Placebo | Overall Condition | 1 | Participants | |
| Caregiver Global Impression of Change (CaGI-C) Scores for the Subject's Overall Condition and for Seizures | XEN496 | Seizure Severity | 1 | Participants | |
| Caregiver Global Impression of Change (CaGI-C) Scores for the Subject's Overall Condition and for Seizures | Placebo | Seizure Severity | 1 | Participants | |
| Change From Baseline in the Caregiver Global Impression of Severity (CaGI-S) for the Subject's Overall Condition and for Seizures | XEN496 | Overall Condition | 0 | Participants | |
| Change From Baseline in the Caregiver Global Impression of Severity (CaGI-S) for the Subject's Overall Condition and for Seizures | Placebo | Overall Condition | 1 | Participants | |
| Change From Baseline in the Caregiver Global Impression of Severity (CaGI-S) for the Subject's Overall Condition and for Seizures | XEN496 | Seizure Severity | 1 | Participants | |
| Change From Baseline in the Caregiver Global Impression of Severity (CaGI-S) for the Subject's Overall Condition and for Seizures | Placebo | Seizure Severity | 0 | Participants | |
| Safety and Tolerability of XEN496 (e.g., Adverse Events) in Pediatric Subjects With KCNQ2-DEE | XEN496 | No. of Subject with any AE | 5 | Participants | |
| Safety and Tolerability of XEN496 (e.g., Adverse Events) in Pediatric Subjects With KCNQ2-DEE | Placebo | No. of Subject with any AE | 3 | Participants | |
| Safety and Tolerability of XEN496 (e.g., Adverse Events) in Pediatric Subjects With KCNQ2-DEE | XEN496 | No. of Subjects with any TEAE | 5 | Participants | |
| Safety and Tolerability of XEN496 (e.g., Adverse Events) in Pediatric Subjects With KCNQ2-DEE | Placebo | No. of Subjects with any TEAE | 3 | Participants | |
| Safety and Tolerability of XEN496 (e.g., Adverse Events) in Pediatric Subjects With KCNQ2-DEE | XEN496 | No. of Subjects with any Treatment Related TEAE | 1 | Participants | |
| Safety and Tolerability of XEN496 (e.g., Adverse Events) in Pediatric Subjects With KCNQ2-DEE | Placebo | No. of Subjects with any Treatment Related TEAE | 0 | Participants | |
| Safety and Tolerability of XEN496 (e.g., Adverse Events) in Pediatric Subjects With KCNQ2-DEE | XEN496 | No. of Subjects with any TEAE leading to discontinuation of study drug | 0 | Participants | |
| Safety and Tolerability of XEN496 (e.g., Adverse Events) in Pediatric Subjects With KCNQ2-DEE | Placebo | No. of Subjects with any TEAE leading to discontinuation of study drug | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04639310/results